VVT1 Citations (1)
Originally described in: Engineered CRISPR-Cas9 nucleases with altered PAM specificities.Kleinstiver BP, Prew MS, Tsai SQ, Topkar VV, Nguyen NT, Zheng Z, Gonzales AP, Li Z, Peterson RT, Yeh JJ, Aryee MJ, Joung JK Nature. 2015 Jun 22. doi: 10.1038/nature14592. PubMed Journal
Articles Citing VVT1
| Articles |
|---|
| Targeted deletion of BCL11A gene by CRISPR-Cas9 system for fetal hemoglobin reactivation: A promising approach for gene therapy of beta thalassemia disease. Khosravi MA, Abbasalipour M, Concordet JP, Berg JV, Zeinali S, Arashkia A, Azadmanesh K, Buch T, Karimipoor M. Eur J Pharmacol. 2019 Jul 5;854:398-405. doi: 10.1016/j.ejphar.2019.04.042. Epub 2019 Apr 27. PubMed |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.